These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 21839403

  • 1. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ, Talbird SE, Cohen C.
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
    Mauskopf J, Lacey L, Kempel A, Simpson K.
    Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
    Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE.
    AIDS; 2008 Oct 01; 22(15):2025-33. PubMed ID: 18784465
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.
    N Engl J Med; 2009 Dec 03; 361(23):2230-40. PubMed ID: 19952143
    [Abstract] [Full Text] [Related]

  • 14. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Oct 06; (10):CD008740. PubMed ID: 20927777
    [Abstract] [Full Text] [Related]

  • 15. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K, THRIVE study group.
    Lancet; 2011 Jul 16; 378(9787):229-37. PubMed ID: 21763935
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD, Holtgrave DR, Pinkerton HJ.
    Arch Intern Med; 1997 Sep 22; 157(17):1972-80. PubMed ID: 9308509
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C, CNA3007 Study Group.
    Antivir Ther; 2003 Apr 22; 8(2):163-71. PubMed ID: 12741629
    [Abstract] [Full Text] [Related]

  • 19. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J.
    AIDS Res Hum Retroviruses; 1999 Apr 10; 15(6):499-508. PubMed ID: 10221527
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.